NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Denileukin diftitox-cxdl (Lymphir) added to NCCN guidelines as a category 2A recommendation for CTCL, based on phase 3 Study 302 showing 36.2% ORR and 8.7% CR rate. The therapy targets IL-2 receptor and received FDA approval a month prior.
Related Clinical Trials
Highlighted Terms
Related News
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Denileukin diftitox-cxdl (Lymphir) added to NCCN guidelines as a category 2A recommendation for CTCL, based on phase 3 Study 302 showing 36.2% ORR and 8.7% CR rate. The therapy targets IL-2 receptor and received FDA approval a month prior.